2a4l › Citations

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH
Eur J Biochem 243 518-26 (1997)
Cited: 356 times
EuropePMC logo PMID: 9030780

Abstract

Cyclin-dependent kinases (cdk) control the cell division cycle (cdc). These kinases and their regulators are frequently deregulated in human tumours. A potent inhibitor of cdks, roscovitine [2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurin e], was identified by screening a series of C2,N6,N9-substituted adenines on purified cdc2/cyclin B. Roscovitine displays high efficiency and high selectivity (Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J.-G. & Moulinoux, J.-P. (1997) Eur. J. Biochem. 243, 527-536). It behaves as a competitive inhibitor for ATP binding to cdc2. We determined the crystal structure of a complex between cdk2 and roscovitine at 0.24-nm (2.4 A) resolution and refined to an Rfactor of 0.18. The purine portion of the inhibitor binds to the adenine binding pocket of cdk2. The position of the benzyl ring group of the inhibitor enables the inhibitor to make contacts with the enzyme not observed in the ATP-complex structure. Analysis of the position of this benzyl ring explains the specificity of roscovitine in inhibiting cdk2. The structure also reveals that the (R)-stereoisomer of roscovitine is bound to cdk2. The (R)-isomer is about twice as potent in inhibiting cdc2/cyclin B than the (S)-isomer. Results from structure/activity studies and from analysis of the cdk2/roscovitine complex crystal structure should allow the design of even more potent cdk inhibitors.

Reviews - 2a4l mentioned but not cited (2)

  1. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. Susanti NMP, Tjahjono DH. Molecules 26 4462 (2021)
  2. Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Wu H, Yao H, He C, Jia Y, Zhu Z, Xu S, Li D, Xu J. Acta Pharm Sin B 12 3548-3566 (2022)

Articles - 2a4l mentioned but not cited (31)

  1. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D, Sperling AS, Fink EC, Gasser JA, Wang LR, Corsello SM, Sellar RS, Jan M, Gillingham D, Scholl C, Fröhling S, Golub TR, Fischer ES, Thomä NH, Ebert BL. Nature 585 293-297 (2020)
  2. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Law ME, Corsino PE, Narayan S, Law BK. Mol Pharmacol 88 846-852 (2015)
  3. Design, Synthesis, Anticancer Evaluation, Enzymatic Assays, and a Molecular Modeling Study of Novel Pyrazole-Indole Hybrids. Hassan AS, Moustafa GO, Awad HM, Nossier ES, Mady MF. ACS Omega 6 12361-12374 (2021)
  4. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Chatterjee A, Cutler SJ, Doerksen RJ, Khan IA, Williamson JS. Bioorg Med Chem 22 6409-6421 (2014)
  5. EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities. Hsin KY, Morgan HP, Shave SR, Hinton AC, Taylor P, Walkinshaw MD. Nucleic Acids Res 39 D1042-8 (2011)
  6. Virtual target screening: validation using kinase inhibitors. Santiago DN, Pevzner Y, Durand AA, Tran M, Scheerer RR, Daniel K, Sung SS, Woodcock HL, Guida WC, Brooks WH. J Chem Inf Model 52 2192-2203 (2012)
  7. In Vitro and In Vivo Studies of Anti-Lung Cancer Activity of Artemesia judaica L. Crude Extract Combined with LC-MS/MS Metabolic Profiling, Docking Simulation and HPLC-DAD Quantification. Goda MS, Nafie MS, Awad BM, Abdel-Kader MS, Ibrahim AK, Badr JM, Eltamany EE. Antioxidants (Basel) 11 17 (2021)
  8. Prediction of specificity-determining residues for small-molecule kinase inhibitors. Caffrey DR, Lunney EA, Moshinsky DJ. BMC Bioinformatics 9 491 (2008)
  9. Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments. Hassan STS. Biomedicines 8 E132 (2020)
  10. Comparative Assessment of the Antioxidant and Anticancer Activities of Plicosepalus acacia and Plicosepalus curviflorus: Metabolomic Profiling and In Silico Studies. Eltamany EE, Goda MS, Nafie MS, Abu-Elsaoud AM, Hareeri RH, Aldurdunji MM, Elhady SS, Badr JM, Eltahawy NA. Antioxidants (Basel) 11 1249 (2022)
  11. Computational Modeling of Kinase Inhibitor Selectivity. Subramanian G, Sud M. ACS Med Chem Lett 1 395-399 (2010)
  12. Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2. Faber EB, Tian D, Burban D, Levinson NM, Hawkinson JE, Georg GI. ACS Chem Biol 15 1759-1764 (2020)
  13. The Effect of Liposomal Diallyl Disulfide and Oxaliplatin on Proliferation of Colorectal Cancer Cells: In Vitro and In Silico Analysis. Alrumaihi F, Khan MA, Babiker AY, Alsaweed M, Azam F, Allemailem KS, Almatroudi AA, Ahamad SR, AlSuhaymi N, Alsugoor MH, Algefary AN, Khan A. Pharmaceutics 14 236 (2022)
  14. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity. Abdel-Rahman AA, Shaban AKF, Nassar IF, El-Kady DS, Ismail NSM, Mahmoud SF, Awad HM, El-Sayed WA. Molecules 26 3923 (2021)
  15. Lipid-Based Nanoparticle Formulation of Diallyl Trisulfide Chemosensitizes the Growth Inhibitory Activity of Doxorubicin in Colorectal Cancer Model: A Novel In Vitro, In Vivo and In Silico Analysis. Alrumaihi F, Khan MA, Babiker AY, Alsaweed M, Azam F, Allemailem KS, Almatroudi AA, Ahamad SR, Alsugoor MH, Alharbi KN, Almansour NM, Khan A. Molecules 27 2192 (2022)
  16. Identification and structural-functional analysis of cyclin-dependent kinases of the cattle tick Rhipicephalus (Boophilus) microplus. Gomes H, Romeiro NC, Braz GR, de Oliveira EA, Rodrigues C, da Fonseca RN, Githaka N, Isezaki M, Konnai S, Ohashi K, da Silva Vaz I, Logullo C, Moraes J. PLoS One 8 e76128 (2013)
  17. Synthesis, Characterization, and Cytotoxicity of New Spirooxindoles Engrafted Furan Structural Motif as a Potential Anticancer Agent. Altowyan MS, Soliman SM, Haukka M, Al-Shaalan NH, Alkharboush AA, Barakat A. ACS Omega 7 35743-35754 (2022)
  18. Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity. Mandour AA, Nassar IF, Abdel Aal MT, Shahin MAE, El-Sayed WA, Hegazy M, Yehia AM, Ismail A, Hagras M, Elkaeed EB, Refaat HM, Ismail NSM. J Enzyme Inhib Med Chem 37 1957-1973 (2022)
  19. Clove Flower Extract (Syzygium aromaticum) Has Anticancer Potential Effect Analyzed by Molecular Docking and Brine Shrimp Lethality Test (BSLT). Aksono EB, Latifah AC, Suwanti LT, Haq KU, Pertiwi H. Vet Med Int 2022 5113742 (2022)
  20. Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations. Nassar IF, Abdel Aal MT, El-Sayed WA, A E Shahin M, Elsakka EGE, Mokhtar MM, Hegazy M, Hagras M, Mandour AA, Ismail NSM. RSC Adv 12 14865-14882 (2022)
  21. Indenyl-thiazole and indenyl-formazan derivatives: Synthesis, anticancer screening studies, molecular-docking, and pharmacokinetic/ molin-spiration properties. Alfaifi GH, Farghaly TA, Magda H Abdellattif. PLoS One 18 e0274459 (2023)
  22. Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors. Shawish I, Nafie MS, Barakat A, Aldalbahi A, Al-Rasheed HH, Ali M, Alshaer W, Al Zoubi M, Al Ayoubi S, De la Torre BG, Albericio F, El-Faham A. Front Chem 10 1078163 (2022)
  23. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313. Talapati SR, Nataraj V, Pothuganti M, Gore S, Ramachandra M, Antony T, More SS, Krishnamurthy NR. Acta Crystallogr F Struct Biol Commun 76 350-356 (2020)
  24. Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity. Rouchal M, Rudolfová J, Kryštof V, Vojáčková V, Čmelík R, Vícha R. Int J Mol Sci 22 12675 (2021)
  25. Coumarin-carbazole based functionalized pyrazolines: synthesis, characterization, anticancer investigation and molecular docking. Patel M, Pandey N, Timaniya J, Parikh P, Chauhan A, Jain N, Patel K. RSC Adv 11 27627-27644 (2021)
  26. GC/MS Analysis, Cytotoxicity, and Antiviral Activities of Annona glabra Hexane Extract Supported by In Silico Study. Soleman DM, Eldahshan OA, Ibrahim MH, Ogaly HA, Galal HM, Batiha GE, Elkousy RH. Molecules 28 1628 (2023)
  27. Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents. Elmorsy MR, Mahmoud SE, Fadda AA, Abdel-Latif E, Abdelmoaz MA. BMC Chem 16 88 (2022)
  28. A New Saponin (Zygo-albuside D) from Zygophyllum album Roots Triggers Apoptosis in Non-Small Cell Lung Carcinoma (A549 Cells) through CDK-2 Inhibition. Eltamany EE, Nafie MS, Hal DM, Abdel-Kader MS, Abu-Elsaoud AM, Ahmed SA, Ibrahim AK, Badr JM, Abdelhameed RFA. ACS Omega 8 30630-30639 (2023)
  29. Design, Synthesis, In Vitro, and In Silico Studies of New N5-Substituted-pyrazolo[3,4-d]pyrimidinone Derivatives as Anticancer CDK2 Inhibitors. Zaki WA, El-Sayed SM, Alswah M, El-Morsy A, Bayoumi AH, Mayhoub AS, Moustafa WH, Awaji AA, Roh EJ, Hassan AHE, Mahmoud K. Pharmaceuticals (Basel) 16 1593 (2023)
  30. Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Salama EE, Youssef MF, Aboelmagd A, Boraei ATA, Nafie MS, Haukka M, Barakat A, Sarhan AAM. Pharmaceuticals (Basel) 16 1724 (2023)
  31. Prediction of kinase-inhibitor binding affinity using energetic parameters. Usha S, Selvaraj S. Bioinformation 12 172-181 (2016)


Reviews citing this publication (60)

  1. Protein kinases--the major drug targets of the twenty-first century? Cohen P. Nat Rev Drug Discov 1 309-315 (2002)
  2. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Vermeulen K, Van Bockstaele DR, Berneman ZN. Cell Prolif 36 131-149 (2003)
  3. To cycle or not to cycle: a critical decision in cancer. Malumbres M, Barbacid M. Nat Rev Cancer 1 222-231 (2001)
  4. Pharmacological inhibitors of cyclin-dependent kinases. Knockaert M, Greengard P, Meijer L. Trends Pharmacol Sci 23 417-425 (2002)
  5. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Gong CX, Iqbal K. Curr Med Chem 15 2321-2328 (2008)
  6. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Mazanetz MP, Fischer PM. Nat Rev Drug Discov 6 464-479 (2007)
  7. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Pharmacol Ther 93 79-98 (2002)
  8. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Peyressatre M, Prével C, Pellerano M, Morris MC. Cancers (Basel) 7 179-237 (2015)
  9. Small-molecule cyclin-dependent kinase modulators. Senderowicz AM. Oncogene 22 6609-6620 (2003)
  10. Roscovitine in cancer and other diseases. Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A, Valius M. Ann Transl Med 3 135 (2015)
  11. The development and therapeutic potential of protein kinase inhibitors. Cohen P. Curr Opin Chem Biol 3 459-465 (1999)
  12. Neural cell cycle dysregulation and central nervous system diseases. Wang W, Bu B, Xie M, Zhang M, Yu Z, Tao D. Prog Neurobiol 89 1-17 (2009)
  13. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Legraverend M, Grierson DS. Bioorg Med Chem 14 3987-4006 (2006)
  14. Chemical inhibitors: a tool for plant cell cycle studies. Planchais S, Glab N, Inzé D, Bergounioux C. FEBS Lett 476 78-83 (2000)
  15. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Senderowicz AM. Oncogene 19 6600-6606 (2000)
  16. CDK inhibition and cancer therapy. Garrett MD, Fattaey A. Curr Opin Genet Dev 9 104-111 (1999)
  17. Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes. Kapdi AR, Fairlamb IJ. Chem Soc Rev 43 4751-4777 (2014)
  18. Cyclin-dependent kinase inhibitors for treating cancer. Toogood PL. Med Res Rev 21 487-498 (2001)
  19. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Senderowicz AM. Leukemia 15 1-9 (2001)
  20. ATP site-directed competitive and irreversible inhibitors of protein kinases. García-Echeverría C, Traxler P, Evans DB. Med Res Rev 20 28-57 (2000)
  21. Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies. Bailon-Moscoso N, Cevallos-Solorzano G, Romero-Benavides JC, Orellana MI. Curr Genomics 18 106-131 (2017)
  22. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Qian F, Wei D, Zhang Q, Yang S. Biomed Pharmacother 59 64-69 (2005)
  23. Targeting tau protein in Alzheimer's disease. Gong CX, Grundke-Iqbal I, Iqbal K. Drugs Aging 27 351-365 (2010)
  24. Structure-based design of cyclin-dependent kinase inhibitors. Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME. Pharmacol Ther 93 125-133 (2002)
  25. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Schang LM, St Vincent MR, Lacasse JJ. Antivir Chem Chemother 17 293-320 (2006)
  26. Cyclin-dependent kinase modulators and cancer therapy. Gallorini M, Cataldi A, di Giacomo V. BioDrugs 26 377-391 (2012)
  27. Designing inhibitors of cyclin-dependent kinases. Hardcastle IR, Golding BT, Griffin RJ. Annu Rev Pharmacol Toxicol 42 325-348 (2002)
  28. Emerging drug profile: cyclin-dependent kinase inhibitors. Blachly JS, Byrd JC. Leuk Lymphoma 54 2133-2143 (2013)
  29. Cyclin-dependent kinase inhibitors: novel anticancer agents. Mani S, Wang C, Wu K, Francis R, Pestell R. Expert Opin Investig Drugs 9 1849-1870 (2000)
  30. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Galons H, Oumata N, Meijer L. Expert Opin Ther Pat 20 377-404 (2010)
  31. Selectivity and potency of cyclin-dependent kinase inhibitors. Sridhar J, Akula N, Pattabiraman N. AAPS J 8 E204-21 (2006)
  32. Tau as a therapeutic target for Alzheimer's disease. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Curr Alzheimer Res 8 666-677 (2011)
  33. Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. Toledo LM, Lydon NB. Structure 5 1551-1556 (1997)
  34. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. J Innate Immun 8 330-349 (2016)
  35. Cell Cycle Regulation and Melanoma. Xu W, McArthur G. Curr Oncol Rep 18 34 (2016)
  36. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Grant S, Roberts JD. Drug Resist Updat 6 15-26 (2003)
  37. Cell cycle regulatory proteins in glomerular disease. Shankland SJ. Kidney Int 56 1208-1215 (1999)
  38. Fluorescent biosensors - probing protein kinase function in cancer and drug discovery. Morris MC. Biochim Biophys Acta 1834 1387-1395 (2013)
  39. Natural products as kinase inhibitors. Liu J, Hu Y, Waller DL, Wang J, Liu Q. Nat Prod Rep 29 392-403 (2012)
  40. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Li Y, Zhang J, Gao W, Zhang L, Pan Y, Zhang S, Wang Y. Int J Mol Sci 16 9314-9340 (2015)
  41. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Abate AA, Pentimalli F, Esposito L, Giordano A. Expert Opin Investig Drugs 22 895-906 (2013)
  42. Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies. Dodge MJ, MacNeil KM, Tessier TM, Weinberg JB, Mymryk JS. Antiviral Res 188 105034 (2021)
  43. Perspectives for cancer therapies with cdk2 inhibitors. Wadler S. Drug Resist Updat 4 347-367 (2001)
  44. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Noble ME, Endicott JA. Pharmacol Ther 82 269-278 (1999)
  45. The Role of CDK5 in Tumours and Tumour Microenvironments. Do PA, Lee CH. Cancers (Basel) 13 E101 (2020)
  46. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery. Martin RD, Hébert TE, Tanny JC. Int J Mol Sci 21 E3354 (2020)
  47. Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. Sharma S, Singh J, Ojha R, Singh H, Kaur M, Bedi PMS, Nepali K. Eur J Med Chem 112 298-346 (2016)
  48. Diverse roles for CDK-associated activity during spermatogenesis. Palmer N, Talib SZA, Kaldis P. FEBS Lett 593 2925-2949 (2019)
  49. Fluorescent biosensors for high throughput screening of protein kinase inhibitors. Prével C, Pellerano M, Van TN, Morris MC. Biotechnol J 9 253-265 (2014)
  50. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia? Wesierska-Gadek J, Krystof V. Ann N Y Acad Sci 1171 228-241 (2009)
  51. Cell cycle modulators for the treatment of lung malignancies. Senderowicz AM. Clin Lung Cancer 5 158-168 (2003)
  52. ATP-noncompetitive inhibitors of CDK-cyclin complexes. Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E. ChemMedChem 4 19-24 (2009)
  53. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. Węsierska-Gądek J, Kramer MP. Expert Opin Investig Drugs 20 1611-1628 (2011)
  54. Conformational diversity of catalytic cores of protein kinases. Sowadski JM, Epstein LF, Lankiewicz L, Karlsson R. Pharmacol Ther 82 157-164 (1999)
  55. Anterior-posterior pattern formation in ciliates. Cole E, Gaertig J. J Eukaryot Microbiol 69 e12890 (2022)
  56. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Senderowicz AM. Hematol Oncol Clin North Am 16 1229-1253 (2002)
  57. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases. Prével C, Kurzawa L, Van TN, Morris MC. Eur J Med Chem 88 74-88 (2014)
  58. Sheep: the first large animal model in nuclear transfer research. Loi P, Czernik M, Zacchini F, Iuso D, Scapolo PA, Ptak G. Cell Reprogram 15 367-373 (2013)
  59. Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Ferrari S, Gentili C. Front Genet 7 128 (2016)
  60. Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. Jawa Y, Yadav P, Gupta S, Mathan SV, Pandey J, Saxena AK, Kateriya S, Tiku AB, Mondal N, Bhattacharya J, Ahmad S, Chaturvedi R, Tyagi RK, Tandon V, Singh RP. Front Oncol 11 676948 (2021)

Articles citing this publication (263)

  1. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. Eur J Biochem 243 527-536 (1997)
  2. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, Jackson SP. Nat Cell Biol 8 37-45 (2006)
  3. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Nat Cell Biol 1 60-67 (1999)
  4. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C. Nat Med 12 1056-1064 (2006)
  5. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. FEBS Lett 496 44-48 (2001)
  6. Structural basis of inhibitor selectivity in MAP kinases. Wang Z, Canagarajah BJ, Boehm JC, Kassisà S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ. Structure 6 1117-1128 (1998)
  7. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. Int J Cancer 102 463-468 (2002)
  8. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR. Chem Biol 7 51-63 (2000)
  9. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. Br J Cancer 96 29-37 (2007)
  10. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. Mol Cell Biol 18 4499-4508 (1998)
  11. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L. Chem Biol 7 411-422 (2000)
  12. Centrosome number is controlled by a centrosome-intrinsic block to reduplication. Wong C, Stearns T. Nat Cell Biol 5 539-544 (2003)
  13. Letter Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Nat Struct Biol 4 796-801 (1997)
  14. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, Ratan RR. J Neurosci 28 163-176 (2008)
  15. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. Schang LM, Phillips J, Schaffer PA. J Virol 72 5626-5637 (1998)
  16. Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis. Grob A, Roussel P, Wright JE, McStay B, Hernandez-Verdun D, Sirri V. J Cell Sci 122 489-498 (2009)
  17. Liposarcoma: molecular genetics and therapeutics. Conyers R, Young S, Thomas DM. Sarcoma 2011 483154 (2011)
  18. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Kim EH, Kim SU, Shin DY, Choi KS. Oncogene 23 446-456 (2004)
  19. Cyclin-dependent kinases govern formation and maintenance of the nucleolus. Sirri V, Hernandez-Verdun D, Roussel P. J Cell Biol 156 969-981 (2002)
  20. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. Pippin JW, Qu Q, Meijer L, Shankland SJ. J Clin Invest 100 2512-2520 (1997)
  21. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P. J Physiol 540 761-770 (2002)
  22. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Proc Natl Acad Sci U S A 108 8414-8419 (2011)
  23. Tipin is required for stalled replication forks to resume DNA replication after removal of aphidicolin in Xenopus egg extracts. Errico A, Costanzo V, Hunt T. Proc Natl Acad Sci U S A 104 14929-14934 (2007)
  24. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Quennet V, Beucher A, Barton O, Takeda S, Löbrich M. Nucleic Acids Res 39 2144-2152 (2011)
  25. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA. Protein Sci 10 2200-2206 (2001)
  26. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. J Virol 79 13778-13793 (2005)
  27. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malim MH, Gray NS, Schaffer PA. J Virol 76 7874-7882 (2002)
  28. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Becker F, Murthi K, Smith C, Come J, Costa-Roldán N, Kaufmann C, Hanke U, Degenhart C, Baumann S, Wallner W, Huber A, Dedier S, Dill S, Kinsman D, Hediger M, Bockovich N, Meier-Ewert S, Kluge AF, Kley N. Chem Biol 11 211-223 (2004)
  29. Foxp3 protein stability is regulated by cyclin-dependent kinase 2. Morawski PA, Mehra P, Chen C, Bhatti T, Wells AD. J Biol Chem 288 24494-24502 (2013)
  30. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. Schang LM, Rosenberg A, Schaffer PA. J Virol 73 2161-2172 (1999)
  31. CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. Falck J, Forment JV, Coates J, Mistrik M, Lukas J, Bartek J, Jackson SP. EMBO Rep 13 561-568 (2012)
  32. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. Schang LM, Rosenberg A, Schaffer PA. J Virol 74 2107-2120 (2000)
  33. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Tripathi SK, Muttineni R, Singh SK. J Theor Biol 334 87-100 (2013)
  34. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV. Ann Oncol 23 1617-1626 (2012)
  35. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Am J Pathol 165 843-853 (2004)
  36. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. Greenberger S, Yuan S, Walsh LA, Boscolo E, Kang KT, Matthews B, Mulliken JB, Bischoff J. J Invest Dermatol 131 2467-2476 (2011)
  37. Inhibition of Aurora A in response to DNA damage. Krystyniak A, Garcia-Echeverria C, Prigent C, Ferrari S. Oncogene 25 338-348 (2006)
  38. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. de Azevedo WF, Canduri F, da Silveira NJ. Biochem Biophys Res Commun 293 566-571 (2002)
  39. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. Sanchez V, McElroy AK, Yen J, Tamrakar S, Clark CL, Schwartz RA, Spector DH. J Virol 78 11219-11232 (2004)
  40. In vivo release of mitotic silencing of ribosomal gene transcription does not give rise to precursor ribosomal RNA processing. Sirri V, Roussel P, Hernandez-Verdun D. J Cell Biol 148 259-270 (2000)
  41. Synthesis and target identification of hymenialdisine analogs. Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Chem Biol 11 247-259 (2004)
  42. The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation. Yarotskyy V, Gao G, Peterson BZ, Elmslie KS. J Physiol 587 551-565 (2009)
  43. Effects of cell cycle dependent kinases inhibitor on nuclear and cytoplasmic maturation of porcine oocytes. Marchal R, Tomanek M, Terqui M, Mermillod P. Mol Reprod Dev 60 65-73 (2001)
  44. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. David-Pfeuty T. Oncogene 18 7409-7422 (1999)
  45. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Moon MJ, Lee SK, Lee JW, Song WK, Kim SW, Kim JI, Cho C, Choi SJ, Kim YC. Bioorg Med Chem 14 237-246 (2006)
  46. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. J Med Chem 59 8667-8684 (2016)
  47. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. Kapasi AJ, Spector DH. J Virol 82 394-407 (2008)
  48. Phosphorylation of threonine 61 by cyclin a/Cdk1 triggers degradation of stem-loop binding protein at the end of S phase. Koseoglu MM, Graves LM, Marzluff WF. Mol Cell Biol 28 4469-4479 (2008)
  49. Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase. Deng W, Lin BY, Jin G, Wheeler CG, Ma T, Harper JW, Broker TR, Chow LT. J Virol 78 13954-13965 (2004)
  50. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Hassan P, Fergusson D, Grant KM, Mottram JC. Mol Biochem Parasitol 113 189-198 (2001)
  51. Phosphorylation of the vesicle-tethering protein p115 by a casein kinase II-like enzyme is required for Golgi reassembly from isolated mitotic fragments. Dirac-Svejstrup AB, Shorter J, Waters MG, Warren G. J Cell Biol 150 475-488 (2000)
  52. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P, Fischer PM, Walkinshaw MD. Structure 11 399-410 (2003)
  53. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. Tamrakar S, Kapasi AJ, Spector DH. J Virol 79 15477-15493 (2005)
  54. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Wojciechowski J, Horky M, Gueorguieva M, Węsierska-Gądek J. Int J Cancer 106 486-495 (2003)
  55. Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Liu B, Preisig PA. Kidney Int 62 1650-1658 (2002)
  56. Phosphorylation of synaptic GTPase-activating protein (synGAP) by Ca2+/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 5 (CDK5) alters the ratio of its GAP activity toward Ras and Rap GTPases. Walkup WG, Washburn L, Sweredoski MJ, Carlisle HJ, Graham RL, Hess S, Kennedy MB. J Biol Chem 290 4908-4927 (2015)
  57. Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Pandey PK, Udayakumar TS, Lin X, Sharma D, Shapiro PS, Fondell JD. Mol Cell Biol 25 10695-10710 (2005)
  58. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E. Clin Cancer Res 16 109-120 (2010)
  59. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D. Cell Cycle 7 2846-2855 (2008)
  60. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, Meijer L. Oncogene 33 5675-5687 (2014)
  61. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. Wesierska-Gadek J, Schmitz ML, Ranftler C. J Cell Biochem 100 865-874 (2007)
  62. Effect of cycloheximide, 6-DMAP, roscovitine and butyrolactone I on resumption of meiosis in porcine oocytes. Le Beux G, Richard FJ, Sirard MA. Theriogenology 60 1049-1058 (2003)
  63. Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition. Borgne A, Ostvold AC, Flament S, Meijer L. J Biol Chem 274 11977-11986 (1999)
  64. Alterations and reversibility in the chromatin, cytoskeleton and development of pig oocytes treated with roscovitine. Ju JC, Tsay C, Ruan CW. Mol Reprod Dev 64 482-491 (2003)
  65. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells. David-Pfeuty T, Nouvian-Dooghe Y, Sirri V, Roussel P, Hernandez-Verdun D. Oncogene 20 5951-5963 (2001)
  66. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Ahn JS, Radhakrishnan ML, Mapelli M, Choi S, Tidor B, Cuny GD, Musacchio A, Yeh LA, Kosik KS. Chem Biol 12 811-823 (2005)
  67. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug. Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. PLoS One 10 e0132072 (2015)
  68. Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. Buraei Z, Schofield G, Elmslie KS. Neuropharmacology 52 883-894 (2007)
  69. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Mol Cancer Ther 15 593-607 (2016)
  70. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Sidén A, Sidén M, Pettersson T, Hassan M. Eur J Pharm Sci 25 91-103 (2005)
  71. Alternative binding modes of an inhibitor to two different kinases. De Moliner E, Brown NR, Johnson LN. Eur J Biochem 270 3174-3181 (2003)
  72. Contribution of high p34cdc2 kinase activity to premature chromosome condensation of injected somatic cell nuclei in rat oocytes. Ito J, Hirabayashi M, Kato M, Takeuchi A, Ito M, Shimada M, Hochi S. Reproduction 129 171-180 (2005)
  73. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Guiffant D, Tribouillard D, Gug F, Galons H, Meijer L, Blondel M, Bach S. Biotechnol J 2 68-75 (2007)
  74. Regulation of Bcl-xL-ATP Synthase Interaction by Mitochondrial Cyclin B1-Cyclin-Dependent Kinase-1 Determines Neuronal Survival. Veas-Pérez de Tudela M, Delgado-Esteban M, Maestre C, Bobo-Jiménez V, Jiménez-Blasco D, Vecino R, Bolaños JP, Almeida A. J Neurosci 35 9287-9301 (2015)
  75. Treatment of Vicia faba root tip cells with specific inhibitors to cyclin-dependent kinases leads to abnormal spindle formation. Binarová P, Dolezel J, Draber P, Heberle-Bors E, Strnad M, Bögre L. Plant J 16 697-707 (1998)
  76. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. Int J Cancer 124 465-472 (2009)
  77. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Ganapathi SB, Kester M, Elmslie KS. Am J Physiol Cell Physiol 296 C701-10 (2009)
  78. Synthesis and biological activity of olomoucine II. Krystof V, Lenobel R, Havlícek L, Kuzma M, Strnad M. Bioorg Med Chem Lett 12 3283-3286 (2002)
  79. PPARgamma1 synthesis and adipogenesis in C3H10T1/2 cells depends on S-phase progression, but does not require mitotic clonal expansion. Cho YC, Jefcoate CR. J Cell Biochem 91 336-353 (2004)
  80. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T. Chem Biol Drug Des 67 46-57 (2006)
  81. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. Huang X, Finerty P, Walker JR, Butler-Cole C, Vedadi M, Schapira M, Parker SA, Turk BE, Thompson DA, Dhe-Paganon S. J Struct Biol 165 88-96 (2009)
  82. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors. Kim DC, Lee YR, Yang BS, Shin KJ, Kim DJ, Chung BY, Yoo KH. Eur J Med Chem 38 525-532 (2003)
  83. Differential inhibitor sensitivity between human kinases VRK1 and VRK2. Vázquez-Cedeira M, Barcia-Sanjurjo I, Sanz-García M, Barcia R, Lazo PA. PLoS One 6 e23235 (2011)
  84. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Harmse L, van Zyl R, Gray N, Schultz P, Leclerc S, Meijer L, Doerig C, Havlik I. Biochem Pharmacol 62 341-348 (2001)
  85. Tau secretion is correlated to an increase of Golgi dynamics. Mohamed NV, Desjardins A, Leclerc N. PLoS One 12 e0178288 (2017)
  86. A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase. Chen HM, Wang L, D'Mello SR. Eur J Neurosci 28 2003-2016 (2008)
  87. Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, Heng HH. Mol Cytogenet 3 20 (2010)
  88. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells. Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O, Maurer M. J Cell Biochem 112 761-772 (2011)
  89. Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. Ye M, Duus KM, Peng J, Price DH, Grose C. J Virol 73 1320-1330 (1999)
  90. Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits. Tran K, Mahr JA, Choi J, Teodoro JG, Green MR, Spector DH. J Virol 82 529-537 (2008)
  91. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD. J Neurosci 33 10559-10567 (2013)
  92. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Filgueira de Azevedo W, Gaspar RT, Canduri F, Camera JC, Freitas da Silveira NJ. Biochem Biophys Res Commun 297 1154-1158 (2002)
  93. Maintenance of meiotic arrest in bovine oocytes using the S-enantiomer of roscovitine: effects on maturation, fertilization and subsequent embryo development in vitro. Coy P, Romar R, Payton RR, McCann L, Saxton AM, Edwards JL. Reproduction 129 19-26 (2005)
  94. Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent. McNeely SC, Taylor BF, States JC. Toxicol Appl Pharmacol 231 61-67 (2008)
  95. Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. Logé C, Testard A, Thiéry V, Lozach O, Blairvacq M, Robert JM, Meijer L, Besson T. Eur J Med Chem 43 1469-1477 (2008)
  96. Stability, pKa and plasma protein binding of roscovitine. Vita M, Abdel-Rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, Meurling L, Hassan M. J Chromatogr B Analyt Technol Biomed Life Sci 821 75-80 (2005)
  97. Structure-guided discovery of cyclin-dependent kinase inhibitors. Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V. Biopolymers 89 372-379 (2008)
  98. Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice. Bangen JM, Hammerich L, Sonntag R, Baues M, Haas U, Lambertz D, Longerich T, Lammers T, Tacke F, Trautwein C, Liedtke C. Hepatology 66 1242-1257 (2017)
  99. Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. Frouin I, Montecucco A, Biamonti G, Hübscher U, Spadari S, Maga G. EMBO J 21 2485-2495 (2002)
  100. Cytotoxic activity and apoptosis-inducing potential of di-spiropyrrolidino and di-spiropyrrolizidino oxindole andrographolide derivatives. Dey SK, Bose D, Hazra A, Naskar S, Nandy A, Munda RN, Das S, Chatterjee N, Mondal NB, Banerjee S, Saha KD. PLoS One 8 e58055 (2013)
  101. Nuclear and cytoplasmic maturation of sow oocytes are not synchronized by specific meiotic inhibition with roscovitine during in vitro maturation. Schoevers EJ, Bevers MM, Roelen BA, Colenbrander B. Theriogenology 63 1111-1130 (2005)
  102. Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Meijer L. Drug Resist Updat 3 83-88 (2000)
  103. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Xie Y, Liu Y, Ma C, Yuan Z, Wang W, Zhu Z, Gao G, Liu X, Yuan H, Chen R, Huang S, Wang X, Zhu X, Wang X, Mao Z, Li M. Neurosci Lett 367 355-359 (2004)
  104. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1. Feichtinger S, Stamminger T, Müller R, Graf L, Klebl B, Eickhoff J, Marschall M. J Gen Virol 92 1519-1531 (2011)
  105. Whether to target single or multiple CDKs for therapy? That is the question. Węsierska-Gądek J, Maurer M, Zulehner N, Komina O. J Cell Physiol 226 341-349 (2011)
  106. Brassinosteroids cause cell cycle arrest and apoptosis of human breast cancer cells. Steigerová J, Oklešťková J, Levková M, Rárová L, Kolář Z, Strnad M. Chem Biol Interact 188 487-496 (2010)
  107. Phosphorylation of RGS9-1 by an endogenous protein kinase in rod outer segments. Hu G, Jang GF, Cowan CW, Wensel TG, Palczewski K. J Biol Chem 276 22287-22295 (2001)
  108. Control of in vitro organogenesis by cyclin-dependent kinase activities in plants. Yamaguchi M, Kato H, Yoshida S, Yamamura S, Uchimiya H, Umeda M. Proc Natl Acad Sci U S A 100 8019-8023 (2003)
  109. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Kovárová H, Hajdúch M, Korínková G, Halada P, Krupicková S, Gouldsworthy A, Zhelev N, Strnad M. Electrophoresis 21 3757-3764 (2000)
  110. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. Kang MS, Lee EK, Soni V, Lewis TA, Koehler AN, Srinivasan V, Kieff E. J Virol 85 2859-2868 (2011)
  111. The therapeutic potential of targeting the cell cycle. Webster KR. Expert Opin Investig Drugs 7 865-887 (1998)
  112. A specific inhibitor of p34(cdc2)/cyclin B suppresses fertilization-induced calcium oscillations in mouse eggs. Deng MQ, Shen SS. Biol Reprod 62 873-878 (2000)
  113. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lin MC. Mol Med Rep 12 6501-6508 (2015)
  114. Biochemical evidence for the activation of distinct subsets of mitogen-activated protein kinases by voltage and defense-related stimuli. Link VL, Hofmann MG, Sinha AK, Ehness R, Strnad M, Roitsch T. Plant Physiol 128 271-281 (2002)
  115. Molecular model for the binary complex of uropepsin and pepstatin. de Azevedo WF, Canduri F, Fadel V, Teodoro LG, Hial V, Gomes RA. Biochem Biophys Res Commun 287 277-281 (2001)
  116. Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation. Bártová I, Koca J, Otyepka M. Protein Sci 17 22-33 (2008)
  117. Structures of human purine nucleoside phosphorylase complexed with inosine and ddI. Canduri F, dos Santos DM, Silva RG, Mendes MA, Basso LA, Palma MS, de Azevedo WF, Santos DS. Biochem Biophys Res Commun 313 907-914 (2004)
  118. Molecular model of shikimate kinase from Mycobacterium tuberculosis. Filgueira de Azevedo W, Canduri F, Simões de Oliveira J, Basso LA, Palma MS, Pereira JH, Santos DS. Biochem Biophys Res Commun 295 142-148 (2002)
  119. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Canduri F, Uchoa HB, de Azevedo WF. Biochem Biophys Res Commun 324 661-666 (2004)
  120. Phosphoproteomic analyses reveal signaling pathways that facilitate lytic gammaherpesvirus replication. Stahl JA, Chavan SS, Sifford JM, MacLeod V, Voth DE, Edmondson RD, Forrest JC. PLoS Pathog 9 e1003583 (2013)
  121. Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines. Libnow S, Methling K, Hein M, Michalik D, Harms M, Wende K, Flemming A, Köckerling M, Reinke H, Bednarski PJ, Lalk M, Langer P. Bioorg Med Chem 16 5570-5583 (2008)
  122. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Testard A, Logé C, Léger B, Robert JM, Lozach O, Blairvacq M, Meijer L, Thiéry V, Besson T. Bioorg Med Chem Lett 16 3419-3423 (2006)
  123. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Liebl J, Krystof V, Vereb G, Takács L, Strnad M, Pechan P, Havlicek L, Zatloukal M, Fürst R, Vollmar AM, Zahler S. Angiogenesis 14 281-291 (2011)
  124. Homology model of the CDK1/cyclin B complex. McGrath CF, Pattabiraman N, Kellogg GE, Lemcke T, Kunick C, Sausville EA, Zaharevitz DW, Gussio R. J Biomol Struct Dyn 22 493-502 (2005)
  125. Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E. Cheng PH, Rao XM, McMasters KM, Zhou HS. PLoS One 8 e57340 (2013)
  126. Retinoid-dependent mRNA expression and poly-(A) contents in bovine oocytes meiotically arrested and/or matured in vitro. Gomez E, Rodríguez A, Goyache F, Díez C, José Royo L, Moreira PN, Néstor Caamaño J, Morán E, Gutiérrez-Adán A. Mol Reprod Dev 69 101-108 (2004)
  127. The anti-apoptosis protein, survivin, mediates gastric epithelial cell cytoprotection against ethanol-induced injury via activation of the p34(cdc2) cyclin-dependent kinase. Jones MK, Padilla OR, Webb NA, Norng M. J Cell Physiol 215 750-764 (2008)
  128. Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors. Dobeš P, Fanfrlík J, Rezáč J, Otyepka M, Hobza P. J Comput Aided Mol Des 25 223-235 (2011)
  129. Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. Weitensteiner SB, Liebl J, Krystof V, Havlíček L, Gucký T, Strnad M, Fürst R, Vollmar AM, Zahler S. PLoS One 8 e54607 (2013)
  130. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. Alzate-Morales JH, Contreras R, Soriano A, Tuñon I, Silla E. Biophys J 92 430-439 (2007)
  131. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Li X, Tanaka K, Nakatani F, Matsunobu T, Sakimura R, Hanada M, Okada T, Nakamura T, Iwamoto Y. Int J Cancer 116 385-394 (2005)
  132. A fluorescence polarization assay for native protein substrates of kinases. Kristjánsdóttir K, Rudolph J. Anal Biochem 316 41-49 (2003)
  133. Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. Yang X, Li H, Liu XS, Deng A, Liu X. J Biol Chem 284 28775-28782 (2009)
  134. Molecular models of NS3 protease variants of the Hepatitis C virus. da Silveira NJ, Arcuri HA, Bonalumi CE, de Souza FP, Mello IM, Rahal P, Pinho JR, de Azevedo WF. BMC Struct Biol 5 1 (2005)
  135. Phosphoprotein-based biomarkers as predictors for cancer therapy. Carter AM, Tan C, Pozo K, Telange R, Molinaro R, Guo A, De Rosa E, Martinez JO, Zhang S, Kumar N, Takahashi M, Wiederhold T, Ghayee HK, Oltmann SC, Pacak K, Woltering EA, Hatanpaa KJ, Nwariaku FE, Grubbs EG, Gill AJ, Robinson B, Gillardon F, Reddy S, Jaskula-Sztul R, Mobley JA, Mukhtar MS, Tasciotti E, Chen H, Bibb JA. Proc Natl Acad Sci U S A 117 18401-18411 (2020)
  136. ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6. Kan Q, Jinno S, Yamamoto H, Kobayashi K, Okayama H. Proc Natl Acad Sci U S A 105 4757-4762 (2008)
  137. Identification of new potential Mycobacterium tuberculosis shikimate kinase inhibitors through molecular docking simulations. Vianna CP, de Azevedo WF. J Mol Model 18 755-764 (2012)
  138. Multiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5. Doucet C, Gutierrez GJ, Lindon C, Lorca T, Lledo G, Pinset C, Coux O. BMC Biochem 6 27 (2005)
  139. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. Wesierska-Gadek J, Schreiner T, Gueorguieva M, Ranftler C. J Cell Biochem 98 1367-1379 (2006)
  140. Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. Hikita T, Oneyama C, Okada M. Genes Cells 15 1051-1062 (2010)
  141. Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription. Kapasi AJ, Clark CL, Tran K, Spector DH. J Virol 83 5904-5917 (2009)
  142. The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels. Buraei Z, Elmslie KS. J Neurochem 105 1450-1461 (2008)
  143. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Wilson SC, Atrash B, Barlow C, Eccles S, Fischer PM, Hayes A, Kelland L, Jackson W, Jarman M, Mirza A, Moreno J, Nutley BP, Raynaud FI, Sheldrake P, Walton M, Westwood R, Whittaker S, Workman P, McDonald E. Bioorg Med Chem 19 6949-6965 (2011)
  144. Mining gene expression data of multiple sclerosis. Guo P, Zhang Q, Zhu Z, Huang Z, Li K. PLoS One 9 e100052 (2014)
  145. Phosphorylation regulates human polη stability and damage bypass throughout the cell cycle. Bertoletti F, Cea V, Liang CC, Lanati T, Maffia A, Avarello MDM, Cipolla L, Lehmann AR, Cohn MA, Sabbioneda S. Nucleic Acids Res 45 9441-9454 (2017)
  146. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Maurer M, Komina O, Wesierska-Gadek J. Ann N Y Acad Sci 1171 250-256 (2009)
  147. Structural bioinformatics study of EPSP synthase from Mycobacterium tuberculosis. Pereira JH, Canduri F, de Oliveira JS, da Silveira NJ, Basso LA, Palma MS, de Azevedo WF, Santos DS. Biochem Biophys Res Commun 312 608-614 (2003)
  148. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L. Bioorg Med Chem Lett 8 793-798 (1998)
  149. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Shrestha CL, Zhang S, Wisniewski B, Häfner S, Elie J, Meijer L, Kopp BT. Sci Rep 10 21700 (2020)
  150. Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases. Spíchal L, Krystof V, Paprskárová M, Lenobel R, Styskala J, Binarová P, Cenklová V, De Veylder L, Inzé D, Kontopidis G, Fischer PM, Schmülling T, Strnad M. J Biol Chem 282 14356-14363 (2007)
  151. Cytokinin N-glucosylation inhibitors suppress deactivation of exogenous cytokinins in radish, but their effect on active endogenous cytokinins is counteracted by other regulatory mechanisms. Blagoeva E, Dobrev PI, Malbeck J, Motyka V, Strnad M, Hanus J, Vanková R. Physiol Plant 121 215-222 (2004)
  152. Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations. Otyepka M, Kríz Z, Koca J. J Biomol Struct Dyn 20 141-154 (2002)
  153. Human DNA helicase B interacts with the replication initiation protein Cdc45 and facilitates Cdc45 binding onto chromatin. Gerhardt J, Guler GD, Fanning E. Exp Cell Res 334 283-293 (2015)
  154. Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis. Chiara M, Menegatti E, Di Simone D, Davit A, Bellis D, Sferch D, De Rosa G, Giachino O, Sena LM, Roccatello D. Clin Exp Immunol 139 225-235 (2005)
  155. Phosphorylation of targeting protein for Xenopus kinesin-like protein 2 (TPX2) at threonine 72 in spindle assembly. Shim SY, Perez de Castro I, Neumayer G, Wang J, Park SK, Sanada K, Nguyen MD. J Biol Chem 290 9122-9134 (2015)
  156. Allostery governs Cdk2 activation and differential recognition of CDK inhibitors. Majumdar A, Burban DJ, Muretta JM, Thompson AR, Engel TA, Rasmussen DM, Subrahmanian MV, Veglia G, Thomas DD, Levinson NM. Nat Chem Biol 17 456-464 (2021)
  157. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, Wipf P, Meriney SD. J Physiol 592 3687-3696 (2014)
  158. Crystal structure of human PNP complexed with guanine. de Azevedo WF, Canduri F, dos Santos DM, Pereira JH, Bertacine Dias MV, Silva RG, Mendes MA, Basso LA, Palma MS, Santos DS. Biochem Biophys Res Commun 312 767-772 (2003)
  159. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells. Wu PC, Tai MH, Hu DN, Lai CH, Chen YH, Wu YC, Tsai CL, Shin SJ, Kuo HK. J Ocul Pharmacol Ther 24 25-33 (2008)
  160. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation. Tripathi SK, Singh SK. Mol Biosyst 10 2189-2201 (2014)
  161. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H. Biochem Pharmacol 76 1503-1514 (2008)
  162. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, Meijer L, Monge A. Bioorg Med Chem 10 2177-2184 (2002)
  163. An in silico approach for the discovery of CDK5/p25 interaction inhibitors. Zhang B, Corbel C, Guéritte F, Couturier C, Bach S, Tan VB. Biotechnol J 6 871-881 (2011)
  164. Evidence that Fas-induced apoptosis leads to S phase arrest. N'cho M, Brahmi Z. Hum Immunol 62 310-319 (2001)
  165. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity. Evers DL, Breitenbach JM, Borysko KZ, Townsend LB, Drach JC. Antimicrob Agents Chemother 46 2470-2476 (2002)
  166. Mitotic and stress-induced phosphorylation of HsPI3K-C2alpha targets the protein for degradation. Didichenko SA, Fragoso CM, Thelen M. J Biol Chem 278 26055-26064 (2003)
  167. Novel pyrazolo[3,4-d]pyrimidine with 4-(1H-benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies. Singla P, Luxami V, Singh R, Tandon V, Paul K. Eur J Med Chem 126 24-35 (2017)
  168. Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation. Orba Y, Sunden Y, Suzuki T, Nagashima K, Kimura T, Tanaka S, Sawa H. Virology 370 173-183 (2008)
  169. Structural basis for inhibition of human PNP by immucillin-H. Filgueira de Azevedo W, Canduri F, Marangoni dos Santos D, Pereira JH, Dias MV, Silva RG, Mendes MA, Basso LA, Palma MS, Santos DS. Biochem Biophys Res Commun 309 917-922 (2003)
  170. Structure-based design of potent CDK1 inhibitors derived from olomoucine. Furet P, Zimmermann J, Capraro HG, Meyer T, Imbach P. J Comput Aided Mol Des 14 403-409 (2000)
  171. Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations. Zhang B, Tan VB, Lim KM, Tay TE, Zhuang S. J Mol Model 13 79-89 (2007)
  172. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Krucher NA, Meijer L, Roberts MH. Cell Mol Neurobiol 17 495-507 (1997)
  173. The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B. Antivir Chem Chemother 20 133-142 (2010)
  174. Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat. Vita M, Meurling L, Pettersson T, Cruz-Sidén M, Sidén A, Hassan M. J Pharm Biomed Anal 34 425-431 (2004)
  175. Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development. Darwiche N, El-Banna S, Gali-Muhtasib H. Expert Opin Drug Discov 2 361-379 (2007)
  176. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro. Song H, Vita M, Sallam H, Tehranchi R, Nilsson C, Sidén A, Hassan Z. Cancer Chemother Pharmacol 60 841-849 (2007)
  177. Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators. Zhang B, Tan VB, Lim KM, Tay TE. J Comput Aided Mol Des 20 395-404 (2006)
  178. Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. Abaza MS, Bahman AM, Al-Attiyah RJ. World J Gastroenterol 14 5162-5175 (2008)
  179. The molecular determinants of R-roscovitine block of hERG channels. Cernuda B, Fernandes CT, Allam SM, Orzillo M, Suppa G, Chia Chang Z, Athanasopoulos D, Buraei Z. PLoS One 14 e0217733 (2019)
  180. 2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors. Moravec J, Krystof V, Hanus J, Havlícek L, Moravcová D, Fuksová K, Kuzma M, Lenobel R, Otyepka M, Strnad M. Bioorg Med Chem Lett 13 2993-2996 (2003)
  181. Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. Steinman RA, Robinson AR, Feghali-Bostwick CA. PLoS One 7 e48560 (2012)
  182. Chemokine signaling links cell-cycle progression and cilia formation for left-right symmetry breaking. Liu J, Zhu C, Ning G, Yang L, Cao Y, Huang S, Wang Q. PLoS Biol 17 e3000203 (2019)
  183. Molecular models of protein kinase 6 from Plasmodium falciparum. Manhani KK, Arcuri HA, da Silveira NJ, Uchôa HB, de Azevedo WF, Canduri F. J Mol Model 12 42-48 (2005)
  184. Phosphorylation Requirement of Murine Leukemia Virus p12. Brzezinski JD, Felkner R, Modi A, Liu M, Roth MJ. J Virol 90 11208-11219 (2016)
  185. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD, Brizuela L, Brenner SL, Stouten PF. J Comput Aided Mol Des 19 111-122 (2005)
  186. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Rajnai Z, Méhn D, Beéry E, Okyar A, Jani M, Tóth GK, Fülöp F, Lévi F, Krajcsi P. Drug Metab Dispos 38 2000-2006 (2010)
  187. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells. Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O, Maurer M. J Cell Biochem 112 1103-1117 (2011)
  188. Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation. Yarotskyy V, Elmslie KS. J Pharmacol Exp Ther 340 463-472 (2012)
  189. Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models. Vauthier V, Ben Saad A, Elie J, Oumata N, Durand-Schneider AM, Bruneau A, Delaunay JL, Housset C, Aït-Slimane T, Meijer L, Falguières T. Sci Rep 9 6653 (2019)
  190. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H. J Cell Biochem 102 1405-1419 (2007)
  191. Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies. Lee K, Nada H, Byun HJ, Lee CH, Elkamhawy A. Pharmaceuticals (Basel) 14 1247 (2021)
  192. Inhibition of Cyclin-dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury. Xu J, Xue Z, Zhang C, Liu Y, Busuttil RW, Zhang J, Kupiec-Weglinski JW, Ji H. Transplantation 103 724-732 (2019)
  193. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease. Wu M, White HV, Boehm BA, Meriney CJ, Kerrigan K, Frasso M, Liang M, Gotway EM, Wilcox MR, Johnson JW, Wipf P, Meriney SD. Neuropharmacology 131 176-189 (2018)
  194. Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. Montanaro G, Bertinaria M, Rolando B, Fruttero R, Lucas CD, Dorward DA, Rossi AG, Megson IL, Gasco A. Bioorg Med Chem 21 2107-2116 (2013)
  195. Physiological responses and endogenous cytokinin profiles of tissue-cultured 'Williams' bananas in relation to roscovitine and an inhibitor of cytokinin oxidase/dehydrogenase (INCYDE) treatments. Aremu AO, Bairu MW, Novák O, Plačková L, Zatloukal M, Doležal K, Finnie JF, Strnad M, Van Staden J. Planta 236 1775-1790 (2012)
  196. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. Vulpetti A, Casale E, Roletto F, Amici R, Villa M, Pevarello P. J Mol Graph Model 24 341-348 (2006)
  197. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates. Wong C, Griffin RJ, Hardcastle IR, Northen JS, Wang LZ, Golding BT. Org Biomol Chem 8 2457-2464 (2010)
  198. The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. Hassan M, Sallam H, Hassan Z. Sultan Qaboos Univ Med J 11 165-178 (2011)
  199. Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition. Liu Y, He X, Sui Y, Yu R, Xu G. FEBS Lett 589 2233-2240 (2015)
  200. Xylocydine, a novel inhibitor of cyclin-dependent kinases, prevents the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic cell death of SK-HEP-1 cells. Ham YM, Choi KJ, Song SY, Jin YH, Chun MW, Lee SK. J Pharmacol Exp Ther 308 814-819 (2004)
  201. A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights. Al-Sanea MM, Obaidullah AJ, Shaker ME, Chilingaryan G, Alanazi MM, Alsaif NA, Alkahtani HM, Alsubaie SA, Abdelgawad MA. Molecules 26 E412 (2021)
  202. Evaluation of ligand-binding affinity using polynomial empirical scoring functions. de Azevedo WF, Dias R. Bioorg Med Chem 16 9378-9382 (2008)
  203. Interactive effects of low temperature and roscovitine (ROS) on meiotic resumption and developmental potential of goat oocytes. Han D, Zhao BT, Liu Y, Li JJ, Wu YG, Lan GC, Tan JH. Mol Reprod Dev 75 838-846 (2008)
  204. Molecular models of protein targets from Mycobacterium tuberculosis. Silveira NJ, Uchôa HB, Pereira JH, Canduri F, Basso LA, Palma MS, Santos DS, de Azevedo WF. J Mol Model 11 160-166 (2005)
  205. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors. Węsierska-Gądek J, Hackl S, Zulehner N, Maurer M, Komina O. J Cell Biochem 112 273-288 (2011)
  206. The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, (57)Fe Mössbauer), theoretical, and biological activity studies. Trávnícek Z, Popa I, Cajan M, Zboril R, Krystof V, Mikulík J. J Inorg Biochem 104 405-417 (2010)
  207. Amino acid sequence conservation of the algesic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain. Chernov AV, Remacle AG, Hullugundi SK, Cieplak P, Angert M, Dolkas J, Shubayev VI, Strongin AY. FEBS J 285 3485-3502 (2018)
  208. Amitozyn impairs chromosome segregation and induces apoptosis via mitotic checkpoint activation. Hermant B, Gudrun A, Potopalsky AI, Chroboczek J, Tcherniuk SO. PLoS One 8 e57461 (2013)
  209. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Li Y, Gao W, Li F, Wang J, Zhang J, Yang Y, Zhang S, Yang L. Mol Biosyst 9 2266-2281 (2013)
  210. Analysis of CDK2 active-site hydration: a method to design new inhibitors. Kríz Z, Otyepka M, Bártová I, Koca J. Proteins 55 258-274 (2004)
  211. Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold. Zhang S, Ulrich M, Gromnicka A, Havlíček L, Kryštof V, Jorda R, Strnad M, Vollmar AM, Zahler S. Br J Pharmacol 173 2645-2656 (2016)
  212. Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA. Tan VB, Zhang B, Lim KM, Tay TE. J Mol Model 16 1-8 (2010)
  213. Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann-Pick type C mice. Zhang M, Hallows JL, Wang X, Bu B, Wang W, Vincent I. J Neurochem 107 814-822 (2008)
  214. Proline-rich domain in dynamin-2 has a low microtubule-binding activity: how is this activity controlled during mitosis in HeLa cells? Morita M, Hamao K, Izumi S, Okumura E, Tanaka K, Kishimoto T, Hosoya H. J Biochem 148 533-538 (2010)
  215. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Molinsky J, Klanova M, Koc M, Beranova L, Andera L, Ludvikova Z, Bohmova M, Gasova Z, Strnad M, Ivanek R, Trneny M, Necas E, Zivny J, Klener P. Leuk Lymphoma 54 372-380 (2013)
  216. Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases. Jackson RC, Barnett AL, McClue SJ, Green SR. Expert Opin Drug Discov 3 131-143 (2008)
  217. Structural bioinformatics study of PNP from Schistosoma mansoni. da Silveira NJ, Uchôa HB, Canduri F, Pereira JH, Camera JC, Basso LA, Palma MS, Santos DS, de Azevedo WF. Biochem Biophys Res Commun 322 100-104 (2004)
  218. Synthesis, characterization and assessment of the cytotoxic properties of cis and trans-[Pd(L)(2)Cl(2)] complexes involving 6-benzylamino-9-isopropylpurine derivatives. Trávnícek Z, Szucová L, Popa I. J Inorg Biochem 101 477-492 (2007)
  219. The design and synthesis of purine inhibitors of CDK2. III. Shum PW, Peet NP, Weintraub PM, Le TB, Zhao Z, Barbone F, Cashman B, Tsay J, Dwyer S, Loos PC, Powers EA, Kropp K, Wright PS, Bitonti A, Dumont J, Borcherding DR. Nucleosides Nucleotides Nucleic Acids 20 1067-1078 (2001)
  220. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Kovarova H, Halada P, Man P, Dzubak P, Hajduch M. Technol Cancer Res Treat 1 247-256 (2002)
  221. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine. Videla-Richardson GA, Furmento VA, Garcia CP, Morris-Hanon O, Sevlever GE, Romorini L, Scassa ME. BMC Mol Cell Biol 20 40 (2019)
  222. Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-Mediated Viral Transcription. Shin Y, Park CM, Kim HG, Kim DE, Choi MS, Kim JA, Choi BS, Yoon CH. Virol Sin 36 254-263 (2021)
  223. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest. Wesierska-Gadek J, Maurer M, Schmid G. J Cell Biochem 102 736-747 (2007)
  224. Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, DFT and empirical calculations. Dobes P, Otyepka M, Strnad M, Hobza P. Chemistry 12 4297-4304 (2006)
  225. N-(indazolyl)benzamido derivatives as CDK1 inhibitors: design, synthesis, biological activity, and molecular docking studies. Raffa D, Maggio B, Cascioferro S, Raimondi MV, Daidone G, Plescia S, Schillaci D, Cusimano MG, Titone L, Colomba C, Tolomeo M. Arch Pharm (Weinheim) 342 265-273 (2009)
  226. Pharmacological Inhibition of Cyclin-Dependent Kinases Triggers Anti-Fibrotic Effects in Hepatic Stellate Cells In Vitro. Hübbers A, Hennings J, Lambertz D, Haas U, Trautwein C, Nevzorova YA, Sonntag R, Liedtke C. Int J Mol Sci 21 E3267 (2020)
  227. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles. Nekardová M, Vymětalová L, Khirsariya P, Kováčová S, Hylsová M, Jorda R, Kryštof V, Fanfrlík J, Hobza P, Paruch K. Chemphyschem 18 785-795 (2017)
  228. Synthesis and biological evaluation of guanidino analogues of roscovitine. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V. Eur J Med Chem 62 443-452 (2013)
  229. Targeting Conformational Activation of CDK2 Kinase. Pellerano M, Tcherniuk S, Perals C, Ngoc Van TN, Garcin E, Mahuteau-Betzer F, Teulade-Fichou MP, Morris MC. Biotechnol J 12 (2017)
  230. The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Hsieh CH, Tang PC, Chang WH, Weng YC, Sha SW, Tseng JK, Chang LH, Ju JC. Theriogenology 65 744-756 (2006)
  231. A Peak of H3T3 Phosphorylation Occurs in Synchrony with Mitosis in Sea Urchin Early Embryos. Feizbakhsh O, Pontheaux F, Glippa V, Morales J, Ruchaud S, Cormier P, Roch F. Cells 9 E898 (2020)
  232. ATF7 is stabilized during mitosis in a CDK1-dependent manner and contributes to cyclin D1 expression. Schaeffer E, Vigneron M, Sibler AP, Oulad-Abdelghani M, Chatton B, Donzeau M. Cell Cycle 14 2655-2666 (2015)
  233. Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2. Kelly MD, Mancera RL. ChemMedChem 1 366-375 (2006)
  234. Exponential repulsion improves structural predictability of molecular docking. Bazgier V, Berka K, Otyepka M, Banáš P. J Comput Chem 37 2485-2494 (2016)
  235. Human cytomegalovirus IE1 protein enhances herpes simplex virus type 1-induced syncytial formation in U373MG cells. Shin KC, Park CG, Hwang ES, Cha CY. J Korean Med Sci 23 1046-1052 (2008)
  236. Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations. Zhang B, Su ZC, Tay TE, Tan VB. J Mol Model 16 1159-1168 (2010)
  237. Synthesis, spectral study and cytotoxicity of platinum(II) complexes with 2,9-disubstituted-6-benzylaminopurines. Malon M, Trávnícek Z, Marek R, Strnad M. J Inorg Biochem 99 2127-2138 (2005)
  238. c-Jun induces apoptosis of starved BM2 monoblasts by activating cyclin A-CDK2. Vanhara P, Bryja V, Horváth V, Kozubík A, Hampl A, Smarda J. Biochem Biophys Res Commun 353 92-97 (2007)
  239. A practical approach to new (5Z) 2-alkylthio-5-arylmethylene-1-methyl-1,5-dihydro-4H-imidazol-4-one derivatives. Bourahla K, Paquin L, Lozach O, Meijer L, Carreaux F, Bazureau JP. Molecules 16 7377-7390 (2011)
  240. Cdk2 activity is dispensable for triggering replicon initiation after transient hypoxia in T24 cells. Stabenow D, Probst H, van Betteraey-Nikoleit M. FEBS J 272 5623-5634 (2005)
  241. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro. Řezníčková E, Weitensteiner S, Havlíček L, Jorda R, Gucký T, Berka K, Bazgier V, Zahler S, Kryštof V, Strnad M. Chem Biol Drug Des 86 1528-1540 (2015)
  242. Chemokine signaling synchronizes angioblast proliferation and differentiation during pharyngeal arch artery vasculogenesis. Liu J, Zhang M, Dong H, Liu J, Mao A, Ning G, Cao Y, Zhang Y, Wang Q. Development 149 dev200754 (2022)
  243. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach. Tripathi SK, Soundarya RN, Singh P, Singh SK. Chem Biol Drug Des 85 107-118 (2015)
  244. Domain analysis of fatty acid synthase protein (NP_217040) from Mycobacterium tuberculosis H37Rv--a bioinformatics study. Ramesh KV, Wagle K, Deshmukh S. J Biomol Struct Dyn 24 393-412 (2007)
  245. Enhancement of Peripheral Nerve Regrowth by the Purine Nucleoside Analog and Cell Cycle Inhibitor, Roscovitine. Law V, Dong S, Rosales JL, Jeong MY, Zochodne D, Lee KY. Front Cell Neurosci 10 238 (2016)
  246. Preliminary cryocrystallography analysis of an eumenine mastoparan toxin isolated from the venom of the wasp Anterhynchium flavomarginatum micado. Delatorre P, Olivieri JR, Ruggiero Neto J, Lorenzi CC, Canduri F, Fadel V, Konno K, Palma MS, Yamane T, de Azevedo WF. Biochim Biophys Acta 1545 372-376 (2001)
  247. Roscovitine in combination with calcium ionophore induces oocyte activation through reduction of M-phase promoting factor activity in mice. Iba T, Yano Y, Umeno M, Hinokio K, Kuwahara A, Irahara M, Yamano S, Yasui T. Zygote 20 321-325 (2012)
  248. The use of R-roscovitine to fit the 'time frame' on in vitro porcine embryo production by intracytoplasmic sperm injection. Alfonso J, García-Rosello E, García-Mengual E, Salvador I, Silvestre MA. Zygote 17 63-70 (2009)
  249. Binding Mechanism of Inhibitors to CDK5/p25 Complex: Free Energy Calculation and Ranking Aggregation Analysis. Wu Q, Kang H, Tian C, Huang Q, Zhu R. Mol Inform 32 251-260 (2013)
  250. Butyrolactone I reversibly alters nuclear configuration, periooplasmic microtubules and development of porcine oocytes. Weng YC, Sha SW, Chiou CM, Tang PC, Yang JH, Ju JC. Theriogenology 67 509-519 (2007)
  251. Catalysis of nucleophilic aromatic substitutions in the 2,6,8-trisubstituted purines and application in the synthesis of combinatorial libraries. Riva-Toniolo C, Müller S, Schaub J, Brill WK. Mol Divers 6 43-53 (2003)
  252. Collaborative Approach between Explainable Artificial Intelligence and Simplified Chemical Interactions to Explore Active Ligands for Cyclin-Dependent Kinase 2. Shimazaki T, Tachikawa M. ACS Omega 7 10372-10381 (2022)
  253. Expression, purification, and circular dichroism analysis of human CDK9. Leopoldino AM, Canduri F, Cabral H, Junqueira M, de Marqui AB, Apponi LH, da Fonseca IO, Domont GB, Santos DS, Valentini S, Bonilla-Rodriguez GO, Fossey MA, de Azevedo WF, Tajara EH. Protein Expr Purif 47 614-620 (2006)
  254. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Wandl S, Wesierska-Gadek J. Ann N Y Acad Sci 1171 242-249 (2009)
  255. Serine/Threonine Protein Phosphatase 2A Regulates the Transport of Axonal Mitochondria. Heo K, Basu H, Gutnick A, Wei W, Shlevkov E, Schwarz TL. Front Cell Neurosci 16 852245 (2022)
  256. Site-Specific Acetyl Lysine Antibodies Reveal Differential Regulation of Histone Acetylation upon Kinase Inhibition. Chen S, Chen S, Duan Q, Xu G. Cell Biochem Biophys 75 119-129 (2017)
  257. Structural studies of shikimate dehydrogenase from Bacillus anthracis complexed with cofactor NADP. Barcellos GB, Caceres RA, de Azevedo WF. J Mol Model 15 147-155 (2009)
  258. Carrying-over effects of GVBD blocking on post-blocking meiotic progression of oocytes: species difference and the signaling pathway leading to MPF activation. Jiao GZ, Lian HY, Gao Y, Sun MJ, Gong S, Zheng LL, Zhang CX, Tan JH. PLoS One 9 e103838 (2014)
  259. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. Quintela M, James DW, Garcia J, Edwards K, Margarit L, Das N, Lutchman-Singh K, Beynon AL, Rioja I, Prinjha RK, Harker NR, Gonzalez D, Steven Conlan R, Francis LW. Br J Cancer 129 163-174 (2023)
  260. In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria. Bhattacharjee AK. Expert Opin Drug Discov 2 1115-1127 (2007)
  261. Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. Tong J, Tan X, Hao S, Ermine K, Lu X, Liu Z, Jha A, Yu J, Zhang L. Oncogene 42 869-880 (2023)
  262. Roscovitine Protects From Arterial Injury by Regulating the Expressions of c-Jun and p27 and Inhibiting Vascular Smooth Muscle Cell Proliferation. Liu Y, Li YF, Chang H, Zhao JS, Hou JM, Yu K, Sun JH, Wang H, Li AY. J Cardiovasc Pharmacol 69 161-169 (2017)
  263. Structural Bioinformatics Approach of Cyclin-Dependent Kinases 1 and 3 Complexed with Inhibitors. Saraiva LA, Veloso MP, Camps I, da Silveira NJ. Mol Inform 30 219-231 (2011)


Related citations provided by authors (2)

  1. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.. De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH Proc Natl Acad Sci U S A 93 2735-40 (1996)
  2. Crystal structure of cyclin-dependent kinase 2.. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH Nature 363 595-602 (1993)

Quick links